New Horizons in Food Allergy: Best Practices & Treatment Advances for Unmet Needs: A Clinical Transfers®

Program Overview

The management of food allergies is rapidly advancing with novel therapies offering hope to millions affected by this disease. Developed in partnership with FARE (Food Allergy Research & Education), this educational program explores the disease- and treatment-related burdens faced by individuals with food allergies, highlighting important unmet needs in underserved communities. You will gain insights into the pathophysiology of food allergies and learn how to apply recent treatment advancements, such as anti-IgE antibody therapy and oral immunotherapy, in clinical practice.

1.0 CE Credit(s)

Expires: November 7, 2025

Target Audience

Primary care physicians, allergists and immunologists, pediatricians, nurses, and other clinicians who treat patients with food allergies.

Educational Objectives

Upon completion of this activity, participants should be better able to:

Identify the disease- and treatment-related burdens of the underserved patient populations with food allergies
Describe the pathophysiology and resulting signs and symptoms of IgE-mediated food allergy
Assess the benefits and limitations of current strategies for managing food allergies
Integrate recent data on biologic therapy for food allergies into clinical practice

Activity Faculty

Anita Roach, MS

Vice President, Health Equity and Community Engagement
FARE (Food Allergy Research & Education)
McLean, VA

R. Sharon Chinthrajah, MD

Associate Professor, Medicine
Associate Professor, Pediatrics
Sean N. Parker Center for Allergy and Asthma Research
Stanford University
Stanford, CA

Edwin H. Kim, MD, MS

Associate Professor, University of North Carolina School of Medicine
Chief, Division of Pediatric Allergy and Immunology
Director, UNC Food Allergy Initiative
Chapel Hill, NC

Supporter Statement

Supported by an educational grant from Genentech, a member of the Roche Group. 

Provider Statement

Jointly provided by RMEI Medical Education, LLC and Food Allergy Research & Education

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Anita Roach, MS, has no relevant financial relationship(s) with ineligible companies to disclose.

R. Sharon Chinthrajah, MD, has relevant financial relationship(s) with Alladapt Immunotherapeutics, Genentech, Intrommune Therapeutics, Latitude, Novartis, Phylaxis (Advisor); Aimmune, DBV, Regeneron (Grants/Research Support).

Edwin H. Kim, MD, MS, has relevant financial relationship(s) with ALK, Cellergy Pharma, DBV Technologies, Genentech, Hanimune Therapeutics, Novartis, Phylaxis Bioscience, Revolo Biotherapeutics, Ukko (Consultant); Genentech, Moonlight Therapeutics (Grants/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers

All planners and managers have no relevant financial relationship(s) with ineligible companies.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by RMEI Medical Education, LLC and Food Allergy Research & Education. RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour(s).

Method of Participation and Request for Credit

To receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at [email protected].

Users must:

Read the learning objectives and faculty disclosures
Participate in the activity
Complete the activity evaluation and attest to credit

There is no fee to participate.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

Featured RMEI CE Activities